Resistance in BRAF and KRAS Mutant Cancers - by Ryan Corcoran, MD, PhD

Dr Ryan Corcoran from MGH talks about #BRAF mutated colorectal cancer updates in this #DocTalkПодробнее

Resistance in Colorectal Cancer by Ryan B. Corcoran, MD, PhDПодробнее

Treatment Options for KRAS-Mutant Unresectable mCRCПодробнее

Dr. Corcoran on Future of Liquid Biopsies in GI CancerПодробнее

Dr. Corcoran on Benefits/Limitations of Liquid Biopsies in GI CancerПодробнее

Dr. Corcoran on Immunotherapy for Microsatellite Stable/Instable CRCПодробнее

Resistance in BRAF and KRAS Mutant CancersПодробнее

Frontiers in Oncology: Ryan Corcoran, MDПодробнее

Adaptive resistance in BRAF- and KRAS-mutated colorectal cancerПодробнее

Liquid Biopsy... - Ryan Corcoran, MGH (D3P9)Подробнее

Dr Argilés on BRAF Mutations in Colorectal CancerПодробнее

2016 WMIF | First Look: Ryan Corcoran, MD, PhD, MGHПодробнее

Dr. Corcoran on the Utility of Regorafenib in CRCПодробнее

Optimal MAPK Inhibition as a Key Component of Therapeutic Strategies for KRAS Mutant CancersПодробнее

Keynote Lecture 4: The BRAF pathway in CRC?Подробнее

Dr. Corcoran on Targeting HER2 Amplification in CRCПодробнее

Ryan Corcoran, MD, explains the need for the MRD test in CRC and whether its ready for prime timeПодробнее

Ryan Corcoran, MD, on the current use of MRD as a valid test for determining GI cancer treatmentПодробнее

Ryan Corcoran, explains cell free DNA and ways to test for itПодробнее